Effectiveness and safety of pidotimod in recurrent respiratory infections in children: a pilot study

T. C. Acharya, Kundan Nivangune, Snehal Muchhala, Rishi Jain


Background: Recurrent respiratory infections (RRIs) are common in children especially in age 1 to 6 years. Pidotimod, an immunostimulant has been found to lower the recurrences of RRIs and improve the quality of life. The Objective of this study was to assess the efficacy and safety of pidotimod in children with recurrent respiratory infections (RRIs).

Methods: In this single-centre, prospective, observational study, children aged 2 to 15 years diagnosed with RRIs were included. RRIs were defined as occurrence of 3 or more episodes of acute respiratory infections (ARIs) or more than 15 days of respiratory symptoms in the past 3 months. These children were treated with pidotimod in addition to standard care treatment. Treatment duration was two months and the follow-up continued for three months. Number of RRIs and severity of RRIs, antibiotic courses and rate of hospitalization before and after treatment were compared.

Results: In total 25 children included in the study, mean age was 7.34±3.63 years. Among them, 68% were males. After treatment with pidotimod, there was significant reduction in mean number of ARI episodes (3.84±0.85 at baseline to 0.48±0.51 at follow-up, p<0.0001). Also, there was significant reduction in the duration of acute infectious episodes (p<0.0001), need of antibiotic courses (p<0.0001) and rates of hospitalization (p<0.0001). No safety concerns were identified and pidotimod was well tolerated.

Conclusions: Addition of pidotimod to the standard treatment in children with RRIs significantly reduces the recurrence, duration of repeat infectious episodes, need of antibiotic treatments and future rates of hospitalizations. These findings support previous data.


Children, Immunostimulant, Pidotimod, Recurrent respiratory infections

Full Text:



Selvaraj K, Chinnakali P, Majumdar A, Krishnan IS. Acute respiratory infections among under-5 children in India: A situational analysis. J Nat Sci Biol Med. 2014;5(1):15-20.

Niederman MS, Krilov LR. Acute lower respiratory infections in developing countries. Lancet. 2013;381(9875):1341-2.

Schaad UB, Esposito S, Razi CH. Diagnosis and Management of Recurrent Respiratory Tract Infections in Children: A Practical Guide. Arch Pediatr Infect Dis. 2015;4(1):e31039.

Raniszewska A, Górska E, Kotuła I, Stelmaszczyk-emmel A, Popko K, Ciepiela O. Recurrent respiratory tract infections in children - analysis of immunological examinations. Eur J Immunol. 2015;40(2):167-73.

El-Azami-El-Idrissi M, Lakhdar-Idrissi M, Chaouki S, Atmani S, Bouharrou A, Hida M. Pediatric recurrent respiratory tract infections: when and how to explore the immune system? (About 53 cases). Pan Afr Med J. 2016;24:53.

Ferrario BE, Garuti S, Braido F, Canonica GW. Pidotimod: the state of art. Clin Mol Allergy. 2015;13(1):8.

Motta G, De Campora E, De Vita C, Esposito S, Galletti C, Incutti V, et al. Immunoactivity of pidotimod against episodes of recurrent tonsillitis in childhood. Arzneimittel-Forschung. 1994;44(12A):1521-4.

Caramia G, Clemente E, Solli R, Mei V, Cera R, Carnelli V, et al. Efficacy and safety of pidotimod in the treatment of recurrent respiratory infections in children. Arzneimittel-Forschung. 1994;44(12A):1480-4.

Walavalkar KCP, Joshi M, Kelkar M, Kulkarni S, Tuteja V, Scaci F. Efficacy and safety of pidotimod as adjuvant in the treatment ofrecurrent upper respiratory tract infections (URTI) in children. Trends Med. 2014;14:11-6.

Das D, Narayanan V, Rathod R, Barkate HV, Sobti V. Efficacy of podotimod in reducing recurrent respiratory tract infections in Indian children. New Indian J Pediatr. 2017;6:101-10.

Cherian T, Ranjini EK, Balasubramaniam KA, Raghupati P. Vitamin A supplementation in children with recurrent respiratory infections. Indian Pediatr. 2001;38(7):771-5.

Nair H, Simõ EAF, Rudan I, Gessner BD, Azziz-Baumgartner E, et al. Global and regional burden of hospital admissions for severe acute lower respiratory infections in young children in 2010 : a systematic analysis. Lancet. 2013;381:1380-90.

Selvaraj K. Acute respiratory infections among under-5 children in India : A situational analysis. J Nat Sci Biol Med. 2014;5(1):15-20.

Del-Rio-Navarro BE, Espinosa-Rosales FJ, Flenady V, Sienra-Monge JJ. Immunostimulants for preventing respiratory tract infection in children (Review). Cochrane Database Syst Rev. 2006;4:CD004974.

Niu H, Wang R, Jia YT, Cai Y. Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: A meta-analysis of randomized controlled trials. Int Immunopharmacol. 2019;67:35-45.

Namazova-Baranova LS, Alekseeva AA, Kharit SM, Kozhevnikova TN, Taranushenko TE, Tuzankina IA, et al. Efficacy and safety of pidotimod in the prevention of recurrent respiratory infections in children: a multicentre study. Int J Immunopathol Pharmacol. 2014;27(3):413-9.